Sign in

NCT00373841Recruiting

Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)

Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis

Source: ClinicalTrials.gov · Last updated 27 Aug 2026

Brief summary (registry, in English)

The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.

Status (registry)
Recruiting
Study type
Observational
Enrollment
500 (estimated)
First submitted
6 Sept 2006
Start date
Oct 2005
Primary completion date
Jul 2030
Lead sponsor
University of Pittsburgh
NCT number
NCT00373841

What you commit to

  • Study type: Observational
  • Planned participants: 500
  • From Oct 2005 to the primary completion date, Jul 2030
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Other Lung Illness

Who the study is looking for

  • Patients who are 18 or older
  • Diagnosis of Idiopathic Pulmonary Fibrosis
  • Treated at the Simmons Center

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Michelle F MacPherson
Coordinator of this site? Confirm its status
PittsburghUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.